MedTrace Logo

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

NCT00710268 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-01-14

No results posted yet for this study

Summary

Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.

Conditions

  • Neoplasm Metastasis

Interventions

DRUG

AZD2281

Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing

DRUG

Bevacizumab

IV administration10 mg/kg every 14 days

Sponsors & Collaborators

Principal Investigators

  • James Carmichael, BSc MBChB MD FRCP · KuDOS Pharmaceuticals Ltd

  • Malcolm Ranson · Christie Hospital, Manchester, UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-03-31
Completion
2009-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710268 on ClinicalTrials.gov